Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids)

International Immunopharmacology

Volumn 1, Issue 6, 2001, Pages 1219-1226

  Sakuma, Shozo ^a   Higashi, Yasuyuki ^a   Sato, Natuki ^a   Sasakawa, Tatsuya ^a   Sengoku, Takanori ^a   Ohkubo, Yoshitaka ^a   Amaya, Tadahiro ^a   Goto, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Atopic dermatitis; CD3 CD2; CD3 CD28; Tacrolimus; Th1 cytokine; Th2 cytokine

Indexed keywords

ALCLOMETASONE DIPROPIONATE; BETAMETHASONE VALERATE; CD2 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOCYTE ANTIBODY; STEROID; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; MONONUCLEAR CELL; OINTMENT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD4; BETAMETHASONE; CELL SEPARATION; CELLS, CULTURED; CYTOKINES; DEPRESSION, CHEMICAL; DERMATITIS, ATOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDICATORS AND REAGENTS; METHYLPREDNISOLONE; MONOCYTES; STEROIDS; TACROLIMUS;

EID: 0035033217     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00059-5     Document Type: Article

References (39)

1. Leung D.Y.M. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin. Exp. Immunol. 107(suppl. 1):1997;25-30.
2. Grewe M., Bruijnzeel-Koomen C.A.F.M., Schopf E., Thepen T., Langeveld-Wildschut A.G.et al. A role for Th1 and Th2 cells in the immuno-pathogenesis of atopic dermatitis. Immunol. Today. 19:1998;359-361.
3. Cooper K.D. Atopic dermatitis: recent trends in pathogenesis and therapy. J. Invest. Dermatol. 102:1994;128-137.
4. Herz U., Bunikowski R., Renz H. Role of T cells in atopic dermatitis. New aspects on the dynamics of cytokine production and the contribution of bacterial superantigens. Int. Arch. Allergy Immunol. 115:1998;179-190.
5. Pene J., Rousset F., Briere F., Chretien I., Bonnefoy J.Y.et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons γ and α and prostaglandin E2. Proc. Natl. Acad. Sci. U. S. A. 85:1988;6880-6884.
6. Geha R.S. Regulation of IgE synthesis in humans. J. Allergy Clin. Immunol. 90:1992;143-150.
7. Sanderson C.J., Campbell H.D., Young I.G. Molecular and cellular biology of eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B cells. Immunol. Rev. 102:1988;29-50.
8. Hamid Q., Boguniewicz M., Leung D.Y.M. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J. Clin. Invest. 94:1994;870-876.
9. Spergel J.M., Mizoguchi E., Oettgen H., Bhan A.K., Geha R.S. Role of Th1 and Th2 cytokines in a murine model of allergic dermatitis. J. Clin. Invest. 103:1999;1103-1111.
10. Sarmiento E.U., Espiritu B.R., Gleich G.J., Thomas L.L. IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor potentiate basophil mediator release stimulated by eosinophil granule major basic protein. J. Immunol. 155:1995;2211-2221.
11. Tai P.C., Sun L., Spry C.J.F. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin. Exp. Immunol. 85:1991;312-316.
12. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M.et al. FK506, a novel immunosuppressant isolated from a streptomyces: II. Immunosuppressive effect of FK506 in vitro. J. Antibiot. 40:1987;1256-1265.
13. Hiroi J., Sengoku T., Morita K., Kishi S., Sato S.et al. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn. J. Pharmacol. 76:1998;175-183.
14. Sengoku T., Morita K., Sakuma S., Motoyama Y., Goto T. Possible inhibitory mechanism of FK506 (tacrolimus hydrate)ointment for atopic dermatitis based on animal models. Eur. J. Pharmacol. 379:1999;183-189.
15. Homey B., Assmann T., Vohr H.W., Ulrich P., Lauerma A.I.et al. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J. Immunol. 160:1998;5331-5340.
16. Nakagawa H., Etoh T., Ishibashi Y., Higaki Y., Kawashima M.et al. Tacrolimus ointment for atopic dermatitis. Lancet. 344:1994;883.
17. Ruzicka T., Bieber T., Schopf E., Rubins A., Dobozy A.et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N. Engl. J. Med. 337:1997;816-821.
18. Tocci M.J., Matkovich D.A., Collier K.A., Kwok P., Dumont F.et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. 143:1989;718-726.
19. Andersson J., Nagy S., Groth C.G., Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology. 75:1992;136-142.
20. Mori A., Suko M., Nishizaki Y., Kaminuma O., Matsuzaki G.et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int. Arch. Allergy Immunol. 104:1994;32-35.
21. + peripheral blood lymphocytes. J. Immunol. 149:1992;3278-3289.
22. Peng X., Kasran A., Bullens D., Ceuppens J.L. Ligation of CD2 provide a strong helper signal for the production of the type 2 cytokines interleukin-4 and -5 by memory T cells. Cell. Immunol. 181:1997;76-85.
23. June C.H., Ledbetter J.A., Linsley P.S., Thompson C.B. Role of the CD28 receptor in T-cell activation. Immunol. Today. 11:1990;211-216.
24. Thompson C.B., Lindsten T., Ledbetter J.A., Kunkel S.L., Young H.A.et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. U. S. A. 86:1989;1333-1337.
25. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol. Today. 13:1992;136-142.
26. Siekierka J.J., Sigal N.H. FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr. Opin. Immunol. 4:1992;548-552.
27. Ho S., Clipstone N., Timmermann L., Northrop J., Graef I.et al. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 80:1996;S40-S45.
28. Thiers B.H. Topical steroid therapy of atopic skin diseases. Allergy Proc. 10:1989;413-416.
29. Korting M.S., Schmid M.H., Korting H.C. Topical glucocorticoids with improved risk-benefit ratio. Drug Saf. 14:1996;375-385.
30. Barnes P.J., Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmcol. Sci. 14:1993;436-441.
31. Beato M. Gene regulation by steroid hormones. Cell. 56:1989;335-344.
32. Ponta H., Cato A.C.B., Herrlich P. Interference of pathway specific transcription factors. Biochim. Biophys. Acta. 1129:1992;255-261.
33. Adcock I.M., Brown C.R., Gelder C.M., Shirasaki H., Peters M.J., Barnes P.J. Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am. J. Physiol. 268:1995;C331-C338.
34. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science. 270:1995;283-286.
35. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science. 270:1995;286-290.
36. Oikarinen A., Haapasaari K.M., Sutinen M., Tasanen K. The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Br. J. Dermatol. 139:1998;1106-1110.
37. Smith J.G., Wehr R.F., Chalker D.K. Corticosteroid-induced cutaneous atrophy and telangiectasia. Arch. Dermatol. 112:1976;1115-1117.
38. Reitamo S., Rissanen J., Remitz A., Granlund H., Erkko P.et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J. Invest. Dermatol. 111:1998;396-398.
39. Ruzicka T., Assmann T., Homey B. Tacrolimus: the drug for the turn of the millennium? Arch. Dermatol. 135:1999;574-580.